Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Debt to Equity (2021 - 2026)

Phathom Pharmaceuticals has reported Debt to Equity over the past 6 years, most recently at -$0.49 for Q1 2026.

  • Quarterly Debt to Equity rose 19.13% to -$0.49 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.49 through Mar 2026, up 19.13% year-over-year, with the annual reading at -$0.48 for FY2025, 39.92% up from the prior year.
  • Debt to Equity was -$0.49 for Q1 2026 at Phathom Pharmaceuticals, down from -$0.48 in the prior quarter.
  • Over five years, Debt to Equity peaked at $5.56 in Q2 2023 and troughed at -$13.2 in Q2 2022.
  • The 5-year median for Debt to Equity is -$0.79 (2024), against an average of -$1.45.
  • Year-over-year, Debt to Equity tumbled 202.46% in 2022 and then skyrocketed 142.09% in 2023.
  • A 5-year view of Debt to Equity shows it stood at -$1.27 in 2022, then plummeted by 48.78% to -$1.89 in 2023, then soared by 58.08% to -$0.79 in 2024, then surged by 39.92% to -$0.48 in 2025, then dropped by 1.79% to -$0.49 in 2026.
  • Per Business Quant, the three most recent readings for PHAT's Debt to Equity are -$0.49 (Q1 2026), -$0.48 (Q4 2025), and -$0.49 (Q3 2025).